Article Text

other Versions

PDF
Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.
  1. S Tariq Sadiq (ssadiq{at}sgul.ac.uk)
  1. St George's, University of London, United Kingdom
    1. M R Pakianathan (mark.pakianathan{at}stgeorges.nhs.uk)
    1. St George's Healthcare NHS Trust, United Kingdom

      Abstract

      The hypersensitivity reaction (HSR) associated with the antiretroviral abacavir does not usually have serious outcomes unless recognised late or following re-challenge. Pharmacogenetic testing of HLA B*5701 (B*5701) for HSR risk is being used increasingly in clinical practice backed by strong evidence among Caucasians and Hispanics1. In the Western Australian landmark studies, updated to improve diagnostic accuracy, positive and negative predictive values (PPV and NPV) of B*5701 for HSR were 78.9% and 99.4%1 respectively. When B*5701 screening was introduced into this cohort2, and in Brighton UK3, no HSR were observed in 148 and 185 B*5701 negative patients respectively treated with abacavir.

      • Abacavir
      • Black African
      • HLA B*5701
      • Hypersensitivity
      • Pharmacogenetics

      Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Linked Articles

      • Brief Encounters
        Helen Ward Rob Miller